Skip to main content
    X

    Xeris Pharmaceuticals Inc (XERS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $16.70
    +0.04 (+0.24%)

    Market Cap: $3.04B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Xeris Pharmaceuticals Inc (XERS) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Xeris Pharmaceuticals reported revenue of $291.85M for the fiscal year ended Dec 31, 2025, up 43.7% from the year before. That year, net income was $554.00K with a net margin of 0.2%, operating cash flow was $28.63M and free cash flow was $27.93M. The quarter ended Sep 30, 2026 had revenue of $107.22M and net income of $11.29M.

    Revenue and Margins

    The operating margin was 8.5% in the fiscal year ended Dec 2025, the highest of the 4 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $1.07M, a compound annual rate of 86.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$291.85M+43.7%85.4%8.5%0.2%
    Dec 2024$203.07M+23.9%81.9%-16.6%-27.0%
    Dec 2023$163.91M+48.7%82.5%-26.8%-38.0%
    Dec 2022$110.25M+122.3%79.5%-74.3%-85.9%
    Dec 2021$49.59M+146.0%73.1%-232.2%-247.5%
    Dec 2020$20.16M+640.4%55.1%-414.5%-452.2%
    Dec 2019$2.72M+10.4%41.1%-4496.0%-4613.5%
    Dec 2018$2.46M+58.4%98.3%-2407.5%-2437.3%
    Dec 2017$1.56M+44.7%99.7%-1711.4%-1706.6%
    Dec 2016$1.07MN/A99.3%-1230.8%-1228.7%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income rose 1718.0% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$291.85M$203.07M$163.91M$110.25M$49.59M$20.16M$2.72M$2.46M$1.56M$1.07M
    Cost of revenue$42.57M$36.83M$28.64M$22.63M$13.32M$9.05M$1.60M$42.00K$4.00K$8.00K
    Gross profit$249.28M$166.24M$135.27M$87.61M$36.27M$11.11M$1.12M$2.42M$1.55M$1.07M
    Research and development$31.16M$25.56M$22.34M$20.97M$25.16M$20.92M$60.44M$40.65M$20.17M$10.24M
    Operating income$24.90M-$33.65M-$44.01M-$81.94M-$115.16M-$83.55M-$122.38M-$59.34M-$26.63M-$13.23M
    Net income$554.00K-$54.84M-$62.26M-$94.66M-$122.72M-$91.14M-$125.58M-$60.08M-$26.55M-$13.21M
    EBITDA$40.96M-$14.37M-$24.71M-$68.93M-$112.61M-$81.02M-$119.57M-$57.22M-$26.38M-$13.09M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$107.22M$92.10M$83.13M$85.81M$74.38M$71.54M$60.12M$60.10M$54.27M$48.06M$40.64M$44.39M
    Gross profit$94.80M$79.59M$72.55M$74.86M$63.38M$59.64M$51.39M$50.62M$40.67M$40.27M$34.67M$29.27M
    Operating income$16.92M$5.17M$7.92M$16.77M$6.73M$4.48M-$3.09M$1.68M-$12.89M-$8.19M-$14.24M-$9.84M
    Net income$11.29M-$31.10M$2.23M$11.08M$621.00K-$1.93M-$9.22M-$5.11M-$15.74M-$15.01M-$18.98M-$13.39M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $220.34M exceeded cash and equivalents by $109.29M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$383.53M$323.06M$322.60M$344.52M$304.36M$159.15M$108.99M$120.03M$45.00M$33.53M
    Current assets$240.31M$167.66M$156.26M$186.82M$142.60M$152.21M$87.48M$117.90M$44.05M$33.17M
    Cash and equivalents$111.04M$71.62M$67.45M$121.97M$67.27M$37.60M$19.52M$45.72M$42.05M$32.27M
    Total liabilities$369.84M$352.68M$329.38M$299.33M$209.13M$125.39M$94.55M$44.62M$102.83M$65.47M
    Short-term debt$0$15.10M$19.11M$0$1.58MN/AN/A$8.21M$2.56M$902.00K
    Long-term debt$220.34M$217.01M$190.93M$187.07M$88.07M$87.02M$58.30M$31.89MN/AN/A
    Shareholder equity$13.69M-$29.61M-$6.78M$45.19M$95.23M$33.76M$14.44M$75.41M-$57.83M-$31.93M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$423.22M$411.90M$392.01M$383.53M$370.19M$334.69M$315.45M$323.06M$321.10M$331.73M$336.62M$322.60M
    Total liabilities$374.44M$421.64M$379.00M$369.84M$371.05M$353.99M$350.58M$352.68M$349.43M$351.02M$345.79M$329.38M
    Cash and equivalents$131.08M$121.75M$111.75M$111.04M$91.60M$59.28M$58.44M$71.62M$59.23M$57.60M$62.69M$67.45M
    Shareholder equity$48.78M-$9.73M$13.01M$13.69M-$861.00K-$19.30M-$35.13M-$29.61M-$28.32M-$19.29M-$9.18M-$6.78M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 97.6% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$28.63M-$36.98M-$47.02M-$102.89M-$95.53M-$80.56M-$104.35M-$56.28M-$24.66M-$16.09M
    Capital expenditures$696.00K$868.00K$2.26M$524.00K$1.08M$377.00K$1.11M$1.51M$700.00K$35.00K
    Free cash flow$27.93M-$37.85M-$49.29M-$103.42M-$96.62M-$80.94M-$105.45M-$57.79M-$25.36M-$16.12M
    Dividends paidN/AN/AN/A$147.05M$25.09M$95.64M$60.68MN/AN/AN/A
    Share repurchasesN/AN/AN/AN/A$54.00K$4.32MN/AN/AN/AN/A
    Investing cash flow-$696.00K$4.88M-$6.00M$34.46M$97.96M-$27.41M-$2.38M-$68.26M-$700.00K-$35.00K
    Financing cash flow$11.39M$36.17M-$1.61M$127.47M$27.25M$126.06M$80.53M$128.21M$35.14M$3.90M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$35.47M$8.26M$9.87M$20.04M$18.43M$182.00K-$10.03M$1.98M-$8.30M-$10.35M-$20.30M$7.47M
    Capital expendituresN/A$209.00K$325.00K$333.00K$71.00K$279.00K$13.00K$220.00K$87.00K$397.00K$164.00K$132.00K
    Free cash flowN/A$8.05M$9.54M$19.71M$18.36M-$97.00K-$10.04M$1.75M-$8.39M-$10.74M-$20.47M$7.34M
    Last 12 quarters

    Frequently Asked Questions About XERS

    What is Xeris Pharmaceuticals' annual revenue?

    Xeris Pharmaceuticals reported revenue of $291.85M for the fiscal year ended Dec 31, 2025.

    How fast is Xeris Pharmaceuticals' revenue growing?

    Revenue was up 43.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 38.3%.

    Is Xeris Pharmaceuticals profitable?

    Yes. Xeris Pharmaceuticals reported net income of $554.00K for the fiscal year ended Dec 31, 2025, with a net margin of 0.2%.

    How much free cash flow does XERS generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $28.63M minus capital expenditures of $696.00K produced free cash flow of $27.93M.

    How much debt does Xeris Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $220.34M, short-term debt of $0 and cash and equivalents of $111.04M.